IL6 and systemic-onset juvenile idiopathic arthritis: Tocilizumab has been suggested as being preferable to IL-1 blocking medications in patients with predominant arthritic symptoms since high levels of IL-6 have been linked to an arthritic presentation in both systemic juvenile idiopathic arthritis (sJIA) and AOSD.